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INTRODUCTION 
Hyperbilirubinemia is a very common problem in the neonates with an 
overall incidence of 70-80% (1). It occurs due to the deposition of bilirubin 
released from breakdown of RBCs and from other non-heme sources in the 
skin and mucus membranes of the newborn.  It is more common in preterm 
babies than full term newborns (2). In the majority of cases jaundice is 
mild and transient. 5-10% of the newborns develop clinically significant 
jaundice requiring intervention (3). Neonatal jaundice remains one of the 
most common reasons for readmission to hospital during the first week of 
life (4).  
Bilirubin Biochemistry (Diagram 1): 
Bilirubin is produced by a two-stage catabolism of haem in the 
reticuloendothelial system. The majority of haem is produced from the 
turnover of haemoglobin released from naturally decommissioned or 
pathologically destroyed erythrocytes. Haem (ferroprotoporphyrin IX) has 
a porphyrin ring structure which is opened by haem oxygenase. The 
intermediate pigment, biliverdin, is water-soluble, non-toxic and serves as 
the excretory product of haem in amphibians, reptiles and birds. In 
mammals, reduction of biliverdin by biliverdin reductase results in the 
production of bilirubin. Bilirubin is an antioxidant in the body and but is 
neurotoxic at high levels (5). 
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Bilirubin Metabolism and Excretion (Diagram 2): 
In the newborn baby bilirubin is produced mainly from the breakdown of 
red cells, with up to a quarter resulting from ineffective erythropoiesis and 
other haem-containing compounds, such as myoglobin and cytochromes. 
Bilirubin is transported in the blood bound reversibly to serum albumin on 
high and low affinity sites, with a potential molar bilirubin to albumin ratio 
of up to 3:1. Under normal circumstances, the amount of free bilirubin 
circulating in the jaundiced newborn is very low.  
Conjugation of bilirubin with glucuronic acid occurs in the smooth 
endoplasmic reticulum to form water-soluble mono and diglucuronides of 
bilirubin in the liver. These reactions are catalysed by the microsomal 
hepatic enzyme uridine diphosphoglucuronosyl transferase (UDPGT). 
Conjugated bilirubin in the form of monoglucuronide, which is more 
predominant form in the newborn, and diglucuronide is actively 
transported out of the liver cell and enters the biliary canaliculi as a 
component of the bile.  
In adults, most of the conjugated bilirubin is converted by colonic flora to 
urobilinogen before elimination in the stool as stercobilinogen. In the 
newborn, a significant amount is hydrolysed by β-glucuronidase in the 
small gut to yield unconjugated bilirubin, which can re-enter the 
circulating pool via the enterohepatic circulation.  
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The Normal Pattern of Neonatal Jaundice: 
The fetus excretes unconjugated bilirubin via the placenta and maternal 
liver. In the absence of fetal hyperbilirubinaemia or maternal liver disease, 
the mean bilirubin level in umbilical cord blood at birth is 1-2 mg/dL. 
Jaundice in the newborns can be physiological or pathological depending 
upon the level and the cause. 
Physiological Hyperbilirubinemia: 
It is the jaundice that is attributable to physiological immaturity of 
neonates to handle increased bilirubin production resulting from an 
immaturity of the liver's excretory pathway for bilirubin at a time of its 
heightened production. Visible jaundice generally appears between 24-72 
hours of age. Total serum bilirubin (TSB) level usually rises in full-term 
infants to reach a peak of 6 to 8 mg/dL by 3 days of age and then falls. A 
rise up to 12mg/dL is in the physiologic range. In premature infants, the 
peak may be 10 to 12 mg/dL on the fifth day of life, possibly rising above 
15 mg/dL without any specific abnormality of bilirubin metabolism (6).  
 
 
 
 
 
12 
 
Pathological Hyperbilirubinemia: 
TSB concentrations have been defined as pathological if concentration 
exceeds 5 mg/dl in first day of life in term neonate, 10 mg/dL on second 
day, or 12-13 mg/dl thereafter (7). Any TSB elevation exceeding 17 mg/dL 
should be presumed to be pathologic and this warrants investigation for a 
cause and possible intervention, such as phototherapy (8). Appearance of 
jaundice within the first 24 hours of life, peak TSB levels above the 
expected normal range, presence of clinical jaundice beyond 2 weeks in 
term babies and beyond 3 weeks in preterms (prolonged jaundice) and 
conjugated bilirubin with dark urine staining the clothes and light colored 
stool would be categorized under pathological jaundice. Certain factors 
exacerbate the jaundice in the newborn as shown in the box below. 
   
 Polycythaemia 
    Delayed cord clamping 
    Maternofetal transfusion 
    Recipient of twin–twin transfusion 
 
   
 Extravasated blood 
    Bruising (e.g. cephalhaematoma) 
    Birth trauma 
    Internal haemorrhage 
 
    Delayed passage of meconium 
    Swallowed blood 
    Hypocaloric feed intake 
    Dehydration 
    Breastfeeding 
    Prematurity 
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Acute Bilirubin Encephalopathy (ABE): 
Bilirubin's toxicity is that of a generalised cellular poison. Disruption of 
membrane function, lowering of action potentials, compromise of energy 
metabolism and disturbance of neurotransmitter synthesis and 
neurotransmission are some of the mechanisms implicated (9). Advances 
in human genomics are identifying factors that predispose to 
hyperbilirubinaemia and bilirubin encephalopathy. There is evidence that 
bilirubin is a substrate for P-glycoprotein, a plasma membrane efflux pump 
found on the luminal surface of brain capillary endothelial cells and 
considered responsible for limiting entry of certain lipophilic substrates 
into the central nervous system (10). P-glycoprotein function may be 
inhibited by drugs. Its expression is also related to gestational maturity, 
and this may be a factor contributing to the greater vulnerability of the 
premature brain to bilirubin neurotoxicity. Also implicated is the 
maturational state of nerve cells exposed to bilirubin, with a greater 
tendency to apoptosis seen in the less well-differentiated astrocytes and 
neurons. 
Clinically it manifests with a myriad of features. The severity is given in 
the form of BIND Score as shown in the table below (11).  
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Bilirubin Induced Neurological Dysfunction (BIND) Score (11)  
 
 
Score of 7 to 9: Represent severe acute bilirubin encephalopathy; urgent 
interventions are recommended to minimize further irreversible brain 
injury.  
Scores of 4 to 6: Represent moderate acute bilirubin encephalopathy 
and is likely to be reversible with urgent bilirubin reduction.  
Scores of 1 to 3: Represent mild acute bilirubin encephalopathy and are 
usually reversible with urgent bilirubin reduction strategies. 
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Chronic Bilirubin Encephalopathy (Kernicterus): 
Kernicterus is the name given to the characteristic pattern of yellow 
staining of parts of the brainstem, hippocampus, cerebellum and certain 
brainstem nuclei (particularly the globus pallidus and subthalamic nucleus) 
due to chronic bilirubin encephalopathy. The clinical manifestations of 
chronic bilirubin encephalopathy arise from the susceptibility to damage of 
the basal ganglia, brainstem auditory pathways and oculomotor nuclei (12). 
This anatomical preference for bilirubin deposition and vulnerability to 
toxicity has not been fully explained, but may be a consequence of 
increased blood flow and metabolic activity in these areas. Regional 
variation in bilirubin influx, detoxification and clearance and the variance 
in neuronal cell inflammatory response are also likely to be implicated. 
 
The long-term features of bilirubin encephalopathy include extrapyramidal 
disturbances, auditory impairment and upward-gaze palsies and dental 
enamel dysplasia (13). The resulting cerebral palsy typically has an 
element of athetosis, which can develop as early as 18 months of age or be 
delayed for several years. High-frequency sensorineural deafness 
frequently accompanies the cerebral palsy, but may evolve in isolation. 
Cognitive impairment can result from bilirubin encephalopathy, but is 
commonly absent. 
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Clinical Examination of Jaundice: 
Kramer described that the dermal staining of bilirubin in the newborns may 
be used as an approximate clinical guide to the level of jaundice (14). In 
the newborn the dermal staining progresses in a cephalo-caudal direction 
due to the difference in the amount of subcutaneous tissue. The neonate 
should be examined in broad daylight. The skin should be blanched by 
digital pressure and the underlying color of skin and subcutaneous tissues 
should be observed. A rough guide for level of dermal staining with level 
of bilirubin is as shown in the table below and diagram number 3 
Kramer’s guide to dermal staining with level of bilirubin (14) 
Area of the body Level of bilirubin 
1.Face 
2.Chest, upper abdomen 
3.Lower abdomen, thighs 
4.Arms, legs 
5.Palms, soles 
4-6 mg/ dl              
6-10 mg/dl 
10-12 mg/dl 
12-15 mg/dl 
>15 mg/dl 
 
Newborns having yellow discoloration of the soles should have a quick 
laboratory confirmation for levels of TSB. Clinical assessment is not very 
reliable and accurate if a newborn has been receiving phototherapy as the 
skin is blanched and also if the baby has dark skin as it may obscure 
jaundice. Transcutaneous bilirubinometer can also be used for screening.                        
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Investigations for Jaundice in the Newborn: the following investigations 
are suggested in a case of neonatal jaundice as shown in the table below. 
Investigations for Jaundice in the Newborn 
Early-onset jaundice Prolonged jaundice 
Total and conjugated serum bilirubin      
Blood group and Direct Coombs' 
Haematocrit and full blood count 
Blood film and reticulocyte count 
Infection screen if indicated 
Serology for congenital infections 
Glucose-6-phosphate dehydrogenase 
screen 
Other red cell enzyme assays if 
feasible 
 
Total and conjugated serum bilirubin 
Thyroid function tests 
Urine culture 
Liver function tests 
IEM work-up 
Chromosomal studies 
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Treatment: 
Two main modalities of treating newborns with hyperbilirubinemia are 
Phototherapy and Double Volume Blood Exchange Transfusion.  
Phototherapy acts by converting insoluble unconjugated bilirubin into 
water soluble products which can be excreted in urine and stools (15-18).  
Double Volume Blood Exchange Transfusion (DVET) helps by 
removing 80-85% of the circulating RBCs and reducing the bilirubin load 
(19, 20).  
The AAP guidelines are widely followed for management of neonatal 
hyperbilirubinemia. The AAP guidelines classify infants as ≥ 35 weeks of 
gestation and < 35 weeks of gestation. 
 
Guidelines for newborn infant ≥ 35 weeks of gestation (21): 
AAP published charts for PT and Double Volume Exchange Transfusion 
(DVET) for newborn infants ≥ 35 weeks of gestation in 2004 are widely 
followed for this purpose as depicted in the diagram number 4 and 5. 
 
Guidelines for newborn infant < 35 weeks of gestation (22): 
For preterm infants < 35 weeks of gestation, the Maisels charts are widely 
used to decide the cut off for phototherapy and exchange transfusion as 
shown in the table given below. 
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Treatment guidelines in infants < 35 weeks of gestation (22) 
Weight (g) Phototherapy (mg/dl) Exchange Transfusion 
(mg/dl) 
<1000 Visible jaundice 10-12 
1000-1500 7-9 12-15 
1500-2000 10-12 15-18 
2000-2500 13-15 18-20 
 
The side-effects of phototherapy and exchange transfusion are as shown 
below. 
Phototherapy Exchange transfusion 
Diarrhea 
 
Increased fluid loss via the skin 
 
Temperature instability 
 
Erythematous rashes 
 
Tanning 
 
Bronze-baby syndrome 
 
Retinal damage 
 
Testicular damage in male babies 
 
Blood-borne infections 
 
Vascular accidents 
 
Cardiac complications 
 
Biochemical disturbances 
 
Haematological disturbances  
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Adjunctive treatments: 
Phenobarbitone, Fluid Supplementation and IVIG have shown promising 
results in a few studies in reducing severe hyperbilirubinemia though more 
evidence is required in this direction. 
 
Phenobarbitone: It induces the activity of uridine-di-phosphate 
glucuronyl transferase (UDPGT) enzyme and helps reducing bilirubin 
levels. It has been shown to be useful in a few studies (23-26). 
 
Fluid Supplementation: Intravenous and oral fluid supplementation has 
been shown to be useful in severe hyperbilirubinemia due to subclinical 
dehydration by increasing the elimination of water soluble photo-products 
of bilirubin formed during phototherapy (27). 
 
IVIG: IVIG therapy inhibits hemolytic breakdown of red blood cells by 
causing non-specific blockade of Fc receptors in the reticuloendothelial 
system and helps reducing hyperbilirubinemia due to ABO and Rh 
incompatability (28, 29). 
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Pre-discharge Estimation of Risk for Hyperbilirubinemia (30): 
Bhutani’s nomogram (30) is widely used to determine the pre-discharge 
risk zone of hyperbilirubinemia in newborns > 35 weeks of gestation as 
shown below in the diagram number 6. 
A significant proportion of neonates develop pathological 
hyperbilirubinemia which is defined as hyperbilirubinemia requiring 
treatment during the first week of life and beyond. Although the outcome 
for the majority is benign, infants with untreated, severe 
hyperbilirubinemia which is defined as serum total bilirubin level >20 
mg/dL, can develop signs of acute bilirubin encephalopathy (ABE). If not 
treated immediately, they might go on to develop kernicterus, a chronic, 
very serious, neurologically devastating condition resulting from bilirubin 
toxicity. To prevent their occurrence prompt management of severe 
hyperbilirubinemia is recommended. Phototherapy is the standard 
treatment for such infants. Phototherapy tends to reduce bilirubin in most 
cases. A significant proportion of babies with severe hyperbilirubinemia 
may not respond to the phototherapy and may go on to require Blood 
Exchange Transfusion (BET), which is a highly invasive procedure with its 
own inherent complications. Subclinical dehydration at presentation due to 
evaporative losses and poor intake of breast milk could be one of main 
reasons for increasing the incidence and severity of jaundice in the 
newborns and may contribute to the failure of phototherapy. It has been 
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suggested that supplemental fluids in the form of increased breast feeds, 
formula feeds or IV fluids can reduce the risk of severe hyperbilirubinemia 
and the need for Blood Exchange Transfusion.  
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BILIRUBIN METABOLISM 
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BILIRUBIN TRANSPORT 
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KRAMER’S GUIDE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Area of the body Level of 
bilirubin 
1.Face 
2.Chest, upper abdomen 
3.Lower abdomen, thighs 
4.Arms, legs 
5.Palms, soles 
4-6 mg/ dl              
6-10 mg/dl 
10-12 mg/dl 
12-15 mg/dl 
>15 mg/dl 
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AAP GUIDELINES FOR PHOTOTHERAPY FOR NEWBORNS >35 
WEEKS OF GESTATION 
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AAP GUIDELINES FOR EXCHANGE TRANSFUSION FOR 
NEWBORNS >35 WEEKS OF GESTATION 
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BHUTANI’S PREDISCHCHARGE RISK NOMOGRAM 
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REVIEW OF LITERATURE 
Boo and Lee (31) in their study compared the rates of decline in serum 
bilirubin levels in severely jaundiced but healthy term infants who were 
given 10% of the daily maintenance fluids as either oral or intravenous 
fluid supplementation during phototherapy. According to them severely 
jaundiced healthy term infants have identical rates of decline in the 
unconjugated bilirubin levels during the first 4 hours of intensive 
phototherapy, irrespective of whether they received fluid supplementation 
by oral or intravenous route. They recommended that all healthy term 
infants with severe and significant hyperbilirubinemia requiring intensive 
phototherapy should be given all of their maintenance and supplemental 
fluid through the enteral route. They reported that the rate of decline in 
serum bilirubin in their newborn patients during the first 4 hours after 
admission was 0.6 mg/hour for the oral group and 0.65 mg/hour for the 
intravenous group. The American Academy of Pediatrics recommends that 
for intensive phototherapy to be effective, it should reduce the serum 
bilirubin levels by 1–2 mg/dL within 4 hours of treatment. This rate of 
decline in serum bilirubin in the study of Boo and Lee, which was greater 
than that recommended by the American Academy of Pediatrics, could be 
possibly explained due to more effective phototherapy lights and/or fluid 
supplementation. However, they also recommended that in order to detect 
a smaller significant difference in the rate of decline in serum bilirubin 
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between oral and intravenous methods of fluid supplementation, a similar 
study with larger sample sizes must be carried out. A limitation of their 
study was they did not have a control group to compare with the two 
methods of fluid supplementation to check out if supplementation of fluid 
was useful at all in the first place. 
In the study done by Iranpour et al (32), sixty healthy term breast-fed 
neonates with non-hemolytic hyperbilirubinemia were assigned randomly 
to receive either breast milk exclusively or intravenous fluid in addition to 
the breast milk during conventional phototherapy. This study showed that, 
the mean total serum bilirubin levels at the time of enrolment and within 
84 hours after phototherapy were not statistically different between the two 
groups. 
Mehta et al (27) conducted a randomized controlled trial of fluid 
supplementation in term healthy neonates with severe hyperbilirubinemia 
enrolling 74 newborns. They were divided into two equal groups. Group 1 
(Control) received phototherapy with usual feeds. Group 2 (Extra fluid) 
received phototherapy with usual Feeds along with extra fluids. Extra 
fluids consisted of IV fluid supplementation with N/5 (0.2%) saline in 5% 
dextrose for a period of 8 hours during phototherapy. The volume of 
supplement included a presumed deficit of 50 mL/kg (equivalent to mild 
dehydration); half of daily maintenance requirements for an 8-hour period, 
which is in accordance with standard norms; and an extra 20 mL/kg/day as 
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allowance for phototherapy. After that babies were given 30 mL/kg/day of 
extra oral feeds (either expressed breast milk or formula) until 
phototherapy was discontinued. Phototherapy was discontinued when two 
TSB values obtained atleast 12 hours apart were < 15 mg/dL.  Exchange 
transfusion was done if at 4 hours into the study TSB increased by 2 
mg/dL or if at 8 hours TSB remained ≥20 mg/dL. They reported in their 
study that fluid supplementation in term neonates presenting with severe 
hyperbilirubinemia decreased the rate of exchange transfusion and duration 
of phototherapy. However, these authors also reported that fluid 
supplementation decreased the rate of exchange transfusion and duration of 
phototherapy more often in the patients with serum osmolality >290 
mOsm/kg compared with the patients fed with breast milk only who also 
had serum osmolality of >290 mOsm/kg; in contrast, fluid supplementation 
did not decrease the rate of exchange transfusion and duration of 
phototherapy in the patients with serum osmolality <290 mOsm/kg 
significantly. 
Reza Saeidi et al (33) conducted a study at Ghaem Hospital in Mashhad, 
Iran from October 2007 to April 2008 to evaluate the role of intravenous 
extra fluid therapy in accelerating the reduction of jaundice in newborns 
who received phototherapy. They enrolled 100 term, jaundiced neonates 
who had a total bilirubin of 18 mg/dl or more. The patients were randomly 
divided into 2 equal groups; group I (case group) was given extra 
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parenteral fluids besides breast feeding, and group II (control group) 
received only breast milk during phototherapy. The rate of bilirubin 
decrement, length of hospital stay, and rate of blood exchange were 
compared. The extra fluid was given as 1/5 normal saline in 5% dextrose at 
a rate of 80 cc/kg for a 2-day-old neonate, and an additional 10 cc/kg each 
day thereafter, to a maximum of 120 cc/kg was administered through the 
peripheral vein during the first 24 hours. Both groups received the same 
type of phototherapy, including fluorescent lamps radiating from a distance 
of 25 cm. They found statistically significant reduction in serum bilirubin 
levels in the first 24 hours. There was no significant difference in exchange 
transfusion rate in the two groups. They concluded that additional 
parenteral fluid therapy in icteric newborns can accelerate reduction in 
serum bilirubin levels in the first 24 hours.  
In Saini et al (34) study, data from two previous randomized controlled 
trials (one published and one unpublished) of fluid supplementation in full-
term neonates with severe non-hemolytic hyperbilirubinemia was used. 
121 newborns with severe jaundice were given fluid supplementation in 
one group, and the other group received only oral feeding. They found that 
fluid supplementation for severe non-hemolytic hyperbilirubinemia is less 
likely to be beneficial in newborns delivered by caesarean/instrumental 
delivery compared to normal vaginal delivery. 
33 
 
A study was carried out in the neonatal intensive care unit of Zeynep at 
Kamil Maternity and Children Hospital (Istanbul, Turkey) over a period of 
four months by Demirsoy et al (35) Two hundred and fifty healthy term 
infants with hyperbilirubinemia were randomized to receive either solely 
breast milk (n=125) or both breast milk and intravenous fluid (n=125) 
during phototherapy. Based on the results of this study, intravenous fluid 
supplementation did not show any beneficial effect on the rate of decrease 
in serum bilirubin and decrease in duration of phototherapy treatment in 
healthy term infants. 
Hazem A Al-Masri (36) conducted a study to evaluate the effectiveness of 
fluid supplementation in jaundiced healthy term infants during 
phototherapy. This prospective study was conducted between September 
2008 and November 2009 at Prince Hashim Hospital and King Hussein 
Medical Centre (KHMC). A total of 80 healthy terms breast-fed and 
formula fed infants with hyperbilirubinemia were assigned randomly into 
two groups: the first group received oral feeds only (n=40) and the other 
group received intravenous fluid in addition to oral fed (n=40). The 
amount of extra fluid which was given to the supplemented group was 
20% of the maintenance. There were no significant differences in the mean 
gestational age, the mean weight and in the mean indirect serum bilirubin 
level at the time of admission to the hospital between the two groups. The 
mean TSB levels within 72 hours after phototherapy were not statistically 
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different between two groups. The conclusion was that in healthy term 
neonates presenting with hyperbilirubinemia, there is no need to add an 
extra fluid during phototherapy and that by only using oral feeding the side 
effect of intravenous cannulation could be avoided. 
Balasubramanian et al (37) conducted a study at the Post Graduate 
Institute of Medical Sciences, Chandigarh, to compare the incidence of 
hyponatremia in      full-term neonates with severe hyperbilirubinemia, 
who received intravenous fluid supplementation with either 0.2% saline in 
5% dextrose or 0.9% saline in 5% dextrose, to prevent blood exchange 
transfusion (BET). In this double-blind, randomized, controlled trial, full-
term newborns (≥37 weeks), appropriate for gestational age, with severe 
non-haemolytic hyperbilirubinemia (serum bilirubin >20 mg⁄dL) were 
enrolled. Eligible neonates were randomized to receive either 0.2% saline 
in 5% dextrose (hypotonic fluid group) or 0.9% saline in 5% dextrose 
(isotonic fluid group) over 8 hrs, in addition to standard phototherapy. The 
amount of fluid supplementation given was the same as given in the study 
by Mehta et al. The decision to stop phototherapy or to treat with BET was 
based on the clinical practice guidelines given by American Academy of 
Pediatrics (AAP) for the treatment of neonatal hyperbilirubinemia. When 
STB was below the phototherapy zone, phototherapy was discontinued and 
rebound value was checked after 12 h. BET was done if, after 4 hours of 
fluid supplementation, STB increased by 2 mg/dL from baseline, or if, at 8 
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hours of fluid supplementation or subsequently at any time, TSB was still 
in the exchange zone. The primary outcome was the number of neonates 
developing hyponatremia (serum Na <135 mmol/L) after 8 hours. The 
secondary outcome variables were the duration of phototherapy, number of 
babies requiring BET, number of babies developing hypernatremia (serum 
Na >145 mmol/L) and the rate of change in serum sodium and TSB. Forty-
two neonates were enrolled and analyzed in each group. Percentage of 
neonates developing hyponatremia after 8 hours was higher in hypotonic 
fluid group as compared to isotonic fluid group (48.8% vs. 10.5%, p 
<0.001). Nevertheless, a larger percentage in isotonic fluid group 
developed hypernatremia (39.5% vs. 12.2%, p <0.001). The rate of BET 
was similar in both groups. They concluded that in full-term neonates with 
severe hyperbilirubinemia, administration of hypotonic fluid to prevent 
BET was associated with a higher incidence of hyponatremia whereas 
isotonic fluid was associated with an increased incidence of hypernatremia. 
Based on a study by Aperia et al and by post hoc analysis they suggested 
that N/3 (0.3%) saline in 5% dextrose might have the least risk of 
hyponatremia as well as hypernatremia as a fluid of choice for fluid 
supplementation. 
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JUSTIFICATION OF STUDY 
Owing to the conflicting reports found in the literature regarding the use of 
fluid supplementation in neonates with severe hyperbilirubinemia in 
preventing BET and reducing the duration of phototherapy and based on 
the suggestion that N/3 (0.3%) saline in 5% dextrose as supplementary 
fluid might have the least risk of hyponatremia as well as hypernatremia, 
the present study was planned and executed. 
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HYPOTHESIS 
 
N/3 (0.3%) saline in 5% dextrose is useful as supplemental fluid therapy in 
term/AGA babies with high levels of non-haemolytic hyperbilirubinemia 
and subclinical dehydration in preventing BET without causing 
Hypo/Hypernatremia.   
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AIMS AND OBJECTIVES 
To compare the efficacy of supplemental fluid therapy in term/AGA babies 
with high levels of non-haemolytic hyperbilirubinemia with N/3 saline in 
5% dextrose versus control in preventing blood exchange transfusion 
(BET). 
. 
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OUTCOME OF THE STUDY 
 
Primary Outcome: 
To evaluate the proportion of term neonates with severe 
hyperbilirubinemia requiring Blood Exchange Transfusion (BET). 
Secondary outcomes: 
 Duration of phototherapy (PT) 
 Percentage drop in TSB at 4, 8 and 24 hours of the study 
 Proportion of neonates developing hyponatremia (serum Na <135 
mmol/L) or hypernatremia (serum Na >145 mmol/L) at the end of 8 
hours and 24 hours of IV fluid supplementation. 
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METHODOLOGY 
Study Centres: 
Department of Neonatology, Institute of Child Health (extramural unit) 
and Institute of Obstetrics and Gynaecology (intramural unit) of Madras 
Medical College, Chennai, Tamilnadu, India. 
Duration of the Study: 
April 2012 to March 2013 
Study Design: 
Prospective randomized controlled trial 
Materials & Methods: 
Subjects: 
 Neonates with severe hyperbilirubinemia with serum bilirubin >20mgs/dL 
admitted to the newborn wards of the Institute of Child Health and Institute 
of Obstetrics & Gynecology Egmore, tertiary care hospitals in Chennai, 
India. 
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Inclusion Criteria: 
Term (≥37 weeks gestation)/AGA neonates presenting with severe non-
hemolytic hyperbilirubinemia (total serum bilirubin [TSB] >20 mg/dL and 
≤25mg/dL 
Exclusion Criteria: 
1. Infants with TSB >25mg/dL (427 mmol/L) 
2. Acute bilirubin encephalopathy (kernicterus) 
3. Evidence of hemolysis (Coombs test positive, peripheral blood smear 
demonstrating evidence of hemolysis or reticulocyte count was >6%) 
4. Obvious signs of dehydration (i.e., sunken fontanel, reduced skin 
turgor, dry mucosa, tachycardia, delayed capillary refill, excessive 
weight loss) 
5. Major congenital malformations 
6. Infants already receiving intravenous (IV) fluids for any reason 
Sample Size: 
A pilot study carried out at the Institute of Child Health in 16 babies with 
severe hyperbilirubinemia (serum bilirubin >20 mg/dL and ≤25mg/dL) 
with 7 babies in the interventional group and 9 babies in the control group. 
1 baby in the interventional group (14%) and 6 babies in the control group 
(66%) required blood exchange transfusion by the predefined criteria 
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which amounted to a difference of more than 50%.  To detect a 50% 
difference in the need for exchange transfusion with 95% confidence        
(α = 0.05) and 80% power (β = 0.2), 84 infants (42 in each group) were 
needed. Hence 84 infants were enrolled in the study after randomization. 
Randomization: 
Permuted block randomization with varying block sizes 
Procedure/Intervention: 
The study group (i.e., the extra fluids group) was given IV fluid 
supplementation with N/3 saline in 5% dextrose for a period of 8 hours 
along with LED phototherapy with an irradiance of around 30µw/cm
2
/nm 
as prescribed by the AAP guidelines on phototherapy. The volume of 
supplement included an assumed deficit of 50 mL/kg (which is equivalent 
to mild dehydration); half of daily maintenance requirements for an 8-hour 
period, which is in accordance with standard norms; and an extra 20 
mL/kg/day was given as a phototherapy allowance. In addition, the infant 
was allowed breast feeds at libitum. At the end of the 8-hour period, IV 
fluids were discontinued. Subsequently, the infant was continued on breast 
feeds at libitum along with the phototherapy until two subsequent bilirubin 
values that were obtained atleast 12 apart were less than the phototherapy 
cutoff. This was the point at which phototherapy was discontinued. The 
control group received LED phototherapy and breast feeds at libitum as 
was given before the randomization procedure. 
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Data collection and Monitoring: 
Body weights, hydration status, feeding details, of the enrolled neonates 
were recorded at baseline. Samples for serum sodium, STB, haematocrit 
and reticulocyte count were also collected at enrollment. Serum sodium 
and STB were measured again after 8 hours of IV fluid supplementation 
and phototherapy in the interventional group or phototherapy alone in the 
control group and again at 24 hours. STB was again measured at 12 hours 
and thereafter every 12 hours till the baby continued to be under 
phototherapy. A rebound STB value was also checked 12 hours after 
discontinuation of phototherapy. Neonates were evaluated daily for body 
weight, hydration status, feeding details, fluids intake, urine output, stool 
frequency and clinical signs of bilirubin encephalopathy. The infants were 
closely monitored till discharge from the hospital. Serum sodium was 
measured by ion-selective electrode method by means of Auto-analyzer. 
Bilirubin was estimated in the lab by diazo method and the values were 
obtained within an hour. The irradiance was measured periodically by a 
standard fluxmeter and kept above 30µwatt/cm
2
/nm. The decision to either 
stop phototherapy or to treat with BET was based on the clinical practice 
guidelines given by American Academy of Pediatrics (AAP) for the 
treatment of neonatal hyperbilirubinemia. When two STB values were 
below the phototherapy zone, phototherapy was discontinued and rebound 
value was checked after 12 h. BET was done if, after 4 h of fluid 
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supplementation, TSB increased by 2 mg/dL from baseline, or if, at 8 
hours of fluid supplementation or subsequently at any time thereafter, 
while under phototherapy, TSB was still in the exchange zone. 
Data Collection Proforma: 
Data was collected in prescribed proforma given in the annexure. 
Statistical Analysis: 
All statistical analysis was performed according to intention to treat 
principle by SPSS software version 18 for Windows (SPSS Inc., Chicago, 
IL, USA). Standard statistical tests were employed. Categorical variables 
were analyzed with chi square test and continuous variables were analyzed 
using student’s t test. Non parametric tests were used if the variables were 
found to be skewed in distribution. Statistical significance was considered 
at a p value of <0.05. 
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FLOW OF PATIENTS IN THE STUDY (CONSORT DIAGRAM) 
 
 
 
 
 
 
 
 
  
 
 
   
 
 
  
 
 
 
 
  
 
                                                                                                     
 
 
No. of babies eligible 
(n = 105) 
 
 
Randomized       
(n = 84) 
Enrollment       
(n = 84) 
Excluded (n = 21) 
Reasons:                                         
 TSB > 25 mg/dL = 6                              
Acute bilirubin encehalopathy = 3 
Evidence of hemolysis = 4                  
Severe dehydration = 1                       
Congenital malformations = 3               
Already on IV fluids = 4 
Fluid Supplementation Group 
(0.3% saline in 5% dextrose)   
(n = 42) 
 
Control Group                           
(n = 42) Allocation 
None lost to follow up 
 
None lost to follow up 
 
Follow-up 
Analysed                                   
(n = 42)                                
None excluded                        
All analysed 
 
Analysed                                   
(n = 42)                                
None excluded                        
All analysed 
 
Analysis 
Blood exchange transfusion = 1 Blood exchange transfusion = 17 
Primary outcome 
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TABLES 
 
Table 1-Baseline Neonatal Demographic Parameters 
Characteristic Fluid 
Supplementation 
Group 
n = 42 
Control Group 
n = 42 
P Value 
Extramural unit (%) 23 (54.8) 25 (59.5) 0.659 
Intramural unit (%) 19 (45.2) 17 (40.5) 0.659 
Gestational age 
(weeks) 
38.7 ± 0.8 39 ± 0.8 0.214 
Males (%) 21 (50) 22 (52.4) 0.827 
Females (%) 21 (50) 20 (47.6) 0.827 
Birth weight (g) 2922 ± 380 2886 ± 331 0.645 
Percent weight loss 5.7 ± 2.8 5.8 ± 2.5 0.924 
Normal vaginal 
delivery (%) 
27 (64.3) 18 (42.8) 0.110 
Instrumental delivery 
(%) 
4 (9.5) 5 (12) 0.110 
Caesarean section (%) 11 (26.2) 19 (45.2) 0.110 
Onset of jaundice 
(day) 
3.0 ± 0.8 2.8 ± 0.8 0.507 
Age at inclusion (day) 4.4 ± 1.5 4.3 ± 1.4 0.675 
 
The neonatal demographic variables that could affect TSB were distributed 
evenly between the fluid supplementation group and the control group. 
(Table 1) 
 
  
 
 
 
 
47 
 
 
 
 
 
 
MODE OF DELIVERY IN THE TWO GROUPS 
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Table 2-Baseline Neonatal Laboratory Parameters 
Characteristic Fluid 
Supplementation 
Group 
n = 42 
Control 
Group 
n = 42 
P Value 
TSB at enrolment 
(mg/dL) 
22 ± 1.7 22 ± 1.8 0.884 
Reticulocyte 
count (%) 
2.1 ± 0.7 2.1 ± 0.8 0.999 
Haematocrit (%) 46.3 ± 3.5 46.5 ± 3.5 0.786 
Serum sodium 
(mmol/L) 
141.7 ± 3.8 143.8 ± 4.8 0.266 
 
The neonatal laboratory variables that could affect TSB were also 
distributed evenly between the fluid supplementation group and the control 
group. (Table 2) 
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Table 3-Baseline Maternal Parameters 
Characteristic  Fluid 
Supplementation 
Group 
n = 42 
Control Group 
n = 42 
P Value 
Maternal age 23.4 ± 3 24.6 ± 2.3 0.190 
Maternal 
hypertension (%) 
2 (4.8) 2 (4.8) 1.000 
Maternal diabetes 
(%) 
1 (2.4) 0 (0) 0.999 
Primigravida  29 (69) 25 (59.5) 0.669 
Second gravida 10 (23.8) 12 (28.6) 0.669 
Third gravida 3 (7.2) 5 (11.9) 0.669 
Primipara 30 (71.4) 27 (64.3) 0.758 
Second para 10 (23.8) 12 (28.6) 0.758 
Third para 2 (4.8) 3 (7.1) 0.758 
First livebirth 30 (71.4) 27 (64.3) 0.643 
Second livebirth 11 (26.2) 12 (28.6) 0.643 
Third livebirth 1 (2.4) 3 (7.1) 0.643 
 
The maternal demographic variables that could affect TSB were also 
distributed evenly between the fluid supplementation group and the control 
group. (Table 3)  
 
 
 
 
 
 
 
 
 
50 
 
 
 
Table 4-Primary Outcome 
Characteristic  Fluid 
Supplementation 
Group 
n = 42 
Control 
Group 
n = 42 
P Value 
Blood exchange 
transfusion (%) 
1 (2.4) 17 (40.5) 0.001 
 
Significantly fewer infants in the fluid supplementation group than in the 
control group (1 [2.4%] vs 17 [40.5%] (p = 0.001); underwent exchange 
transfusion. (Table 4) 
 
 
 
Table 5-Primary Outcome Relative Risk and 95% CI (Inferential 
Statistics) 
Characteristic Relative risk 95% CI P Value 
Blood exchange 
transfusion 
0.06 0.01-0.42 0.002 
 
The relative risk = 0.06; 95% CI = 0.01 to 0.42 (p = 0.002) (Table 5) 
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BLOOD EXCHANGE TRANSFUSION (BET) REQUIRED 
PERCENTAGES BETWEEN THE TWO GROUPS 
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KAPLAN MEIER CURVES SHOWING THE PROBABILITY OF 
BLOOD EXCHANGE TRANSFUSION IN THE TWO GROUPS 
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Table 6-Secondary outcome 
Characteristic Fluid 
Supplementation 
Group 
n = 41 
Control 
Group 
n = 25 
P Value 
Phototherapy 
duration excluding 
BET in hours 
(Mean ± SD) 
26.1 ± 6.5 31.2 ± 8.4 0.013 
 
The mean duration of phototherapy after inclusion in the study was 5.1 
hours shorter in the fluid supplementation group (26 ± 6.5 hours vs 31 ± 
8.4 hours; p = 0.013) (Table 6). 
The irradiance of phototherapy units was similar in the 2 groups 
(≥30µW/cm2/nm). 
Both the groups were on exclusive breast feeding during the entire period 
of phototherapy. 
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MEAN DURATION OF PHOTOTHERAPY BETWEEN THE TWO 
GROUPS 
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KAPLAN MEIER CURVES SHOWING THE PROBABILITY OF 
REMAINING UNDER PHOTOTHERAPY IN THE TWO GROUPS 
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Table 7-Total Serum Bilirubin (TSB) Trends 
Hours of 
Study 
 Fluid Supplementation 
Group 
Control Group P value 
n TSB in 
mg/dL 
Percent 
(%) Fall in 
TSB 
n TSB in 
mg/dL 
Percent 
(%) Fall in 
TSB 
At 
inclusion 
42 22 ± 1.7 - 42 22 ± 1.8 - 0.884 
4 hours 41 19.3 ± 
2.0 
12.4 ± 5.4 35 21.3 ± 
2.6 
6.0 ± 3.9 0.001 
8 hours 41 17.4 ± 
1.4 
20.1 ± 6.1 25 19.9 ± 
3.3 
14.4 ± 5.1 0.001 
24 hours 41 13.6 ± 
1.6 
37.4 ± 8.2 25 14.0 ± 
1.6 
33.5 ± 6.6 0.049 
 
The number of babies at 4, 8 and 24 hours is less than that at inclusion because it 
excludes TSB data of babies who underwent exchange transfusion before that time. 
 
                                         TSB at inclusion - TSB at specific time  × 100 
*Percent (%) fall in TSB =              
                                                           TSB at inclusion 
 
 
 
TSB levels were similar in the 2 groups at inclusion but were significantly 
lower at 4 and 8 hours in the fluid supplementation group. The percentage 
drop in TSB at 4, 8, and 24 hours of study was also significantly greater in 
the fluid supplementation group. (Table 7) 
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TRENDS IN TOTAL SERUM BILIRUBIN (TSB) IN THE TWO 
GROUPS 
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Table 8-Secondary Outcome 
Characteristic 
 
 Fluid 
Supplementation 
Group 
n = 42 
Control Group 
n = 42 
P Value 
Serum sodium at 
inclusion (Mean ± SD) 
141.7 ± 3.8 143.8 ± 4.8 0.266 
Serum sodium at 8 
hours (Mean ± SD) 
143.8 ± 3.3 143.5 ± 4.6 0.767 
Serum sodium at 24 
hours (Mean ± SD) 
141.7 ± 2.7 142.2 ± 3.1 0.419 
 
Serum sodium at 0, 8 and 24 hours was similar in both the groups and no 
significant disturbances in sodium homeostasis (hyponatremia or 
hypernatremia) occurred in either fluid supplementation group or control 
group. (Table 8) 
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TRENDS IN SERUM SODIUM IN THE TWO GROUPS 
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Table 9-Complications  
Complication Fluid Supplementation 
Group 
Control Group 
Bilirubin encephalopathy None None 
Dehydration  None None 
Over hydration None None 
Thrombophlebitis None None 
Sepsis None none 
 
None of the infants in either of the groups developed features of bilirubin 
encephalopathy, any subsequent episodes of dehydration or over hydration, 
serious thrombophlebitis, or evidence of sepsis. (Table 9) 
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DISCUSSION 
In our study infants with serum bilirubin of >20 and ≤25 mg/dL were 
chosen for study as in accordance with the American Academy of 
Pediatrics (AAP) guidelines for managing hyperbilirubinemia in newborns 
>35 weeks gestation, exchange transfusion is usually done at TSB >25 
mg/dL (427 mmol/L). Exchange transfusion carries a mortality rate of 
approximately 3 in 1000 procedures. Significant morbidity in the form of 
apnea, bradycardia, cyanosis, vasospasm, thrombosis, necrotizing 
enterocolitis occurs in as many as 5% of BETs, the risk of mortality is 
0.3% and the risks associated with the use of blood products must always 
be taken into consideration. Incidence of complications may be higher in 
developing countries. Phototherapy units, although simple, are also 
expensive and difficult to maintain. Phototherapy for long hours also has 
its own attendant complications. If providing fluid supplementation 
decreases the need for exchange transfusion and reduces the need for 
phototherapy without undue risks, then it should be cost effective and must 
be considered. 
 
In our study appropriate for gestation term neonates with non hemolytic 
hyperbilirubinemia were enrolled following permuted block 
randomization, generated by computer software, to evenly match the 
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groups and to negate the effect of potential confounding factors. Blinding 
could not be done in this randomized controlled trial; however, the 
laboratory personnel performing the TSB and other biochemical 
investigations were sent coded samples and were unaware of the group 
allocation. The study design was able to ensure matching of demographic 
variables and other factors that could affect the subsequent TSB levels. 
 
According to the AAP recommendations, a weight loss of >12% is an 
indicator of significant dehydration (21). Mild dehydration may be subtle 
and may not produce prominent clinical signs; therefore, weight loss and 
other clinical signs may not manifest sufficiently enough to make a 
diagnosis of mild dehydration. Serum osmolality of >290 mosm/kg could 
give an indication but unfortunately it could not be done in the present 
study. Serum sodium was done which could act as a surrogate marker of 
subclinical dehydration. The fact that in our study neonates with severe 
hyperbilirubinemia were either normonatremic or hypernatremic and none 
hyponatremic probably stresses the same. In our study the volume of 
calculated fluid deficit along with half of the maintenance requirements 
and the phototherapy requirements was given by the IV route rather than 
oral route, because the effectiveness of oral rehydration, though good 
enough, may not be sufficiently reliable and quick in the setting of severe 
hyperbilirubinemia. One of the contemplated mechanisms by which fluid 
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supplementation could have helped is expansion of intravascular volume, 
leading to dilutional lowering of TSB. The more important effect would 
be enhanced renal, biliary and bowel functions. This is because the photo 
products of bilirubin formed during phototherapy are eliminated in the 
urine and stools. Breast feeds at libitum that accompanied and followed the 
initial IV fluid supplementation possibly helped by decreasing 
enterophepatic circulation and thereby interrupting the reabsorption of 
bilirubin from the gut.  We did not give any formula feeds to both the 
groups based on our unit policy and also because we did not want to 
interrupt the mother child bonding. It has been suggested of late that 
breast-fed infants can autoregulate and increase milk intake and decrease 
the insensible water loss as well while receiving phototherapy; however, it 
may not always be true. It is possible that the breast milk output may not 
increase or the feeding may not get augmented because infants when 
exposed to phototherapy tend to become more sleepy than usual. This 
would suggest that we cannot satisfactorily rely on the infants’ own auto-
regulatory mechanisms to augment the intake of breast milk in the 
presence of severe hyperbilirubinemia. IV site complications can be 
minimized by strict adherence to asepsis and proper care. None of these 
were observed in our study. 
The incidence of BET and the duration of phototherapy along with the 
percentage drop in TSB at 0, 4, 8 and 24 hours were significantly less 
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reaching statistical significance in the fluid supplementation group than the 
control group which is in concordance with the earlier studies. Perhaps the 
effect was complemented in our study by the use of blue light LED 
phototherapy with an irradiance of atleast 30µwatts/cm
2
/nm (38). 
The IV fluid chosen for supplementation was N/3 saline in 5% dextrose 
(Fresinius Kabi) based on the suggestion of earlier study by 
Balasubramanian et al (37) which was further based on the suggestion by 
Aperia et al. In our study no statistically significant difference in sodium 
homeostasis occurred though in the study by Balasuramanian et al (37) the 
use of N/5 saline in 5% dextrose (hypotonic saline) resulted in 
hyponatremia and use of NS in 5% dextrose (isotonic saline) resulted in 
hypernatremia. Perhaps the use of N/3 saline in 5% dextrose maintained 
the normal sodium balance. The serum sodium at 0, 8 and 24 hours was 
not statistically different between the two groups. 
Hansen (39) reported in their study 4 infants with serum bilirubin levels 
ranging from 32.1 to 36.3 mg/dL in whom phototherapy decreased TSB by 
>10 mg/dL in 2 to 5 hours. However, of these 4 infants, 3 were clinically 
dehydrated, 2 received IV fluids, and all received oral supplements. These 
findings lend support to the role of rehydration and decreasing 
enterophepatic circulation in audmenting the effects of phototherapy. The 
fluid supplementation given in our study was mainly for mild dehydration 
which could be subclinical in presentation. Mothers were encouraged to 
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breast feed more often to interrupt enterophepatic circulation naturally. 
The strategy was successful in significantly reducing the need for blood 
exchange transfusion and reducing the duration of phototherapy. 
The trial by Boo and Lee (31) compared IV and oral fluid 
supplementation. They reported severely jaundiced healthy term infants 
had similar rates of decrease in TSB levels during the first 4 hours of 
intensive phototherapy, irrespective of whether they received oral or 
intravenous fluid supplementation. But they did not have a control group to 
determine whether fluid supplementation itself played any role. The study 
included infants with clinical dehydration as well as no dehydration, and 
actual fluid intakes were not reported. In our study we chose to give IV 
fluid supplementation along with feeds at libitum to avoid the uncertainty 
of oral feeding as we were dealing with severe hyperbilirubinemia in term 
neonates which could be detrimental if not managed promptly. 
In the study done by Iranpour (32), sixty healthy breast-fed neonates with 
non-hemolytic hyperbilirubinemia were assigned randomly to receive 
either breast milk exclusively or intravenous fluid in addition to breast 
milk during conventional phototherapy. Neonates in the fluid-
supplemented group received an additional 25% of their maintenance fluid 
requirement. They showed that, the mean total serum bilirubin levels at the 
time of enrollment and within 84 hours after phototherapy were not 
statistically different between two groups. This was probably because the 
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IV supplementary fluid given by them was only 25% and that too over an 
extended period of 24 hours. This fluid supplementation was perhaps not 
sufficient to correct the mild subclinical dehydration with 5% fluid deficit 
in term babies with severe non-hemolytic hyperbilirubinemia which needs 
atleast 50ml/kg over a shorter span of time. Using this strategy we were 
able to show statistically significant reduction in the need for blood 
exchange transfusion and the duration of phototherapy in these infants. 
In the study done by Mehta et al (27) which is the harbinger of our study, 
the study group of term neonates with severe non-hemolytic 
hyperbilirubinemia, (i.e., the extra fluids group) was given IV fluid 
supplementation with N/5 (0.2%) saline in 5% dextrose for a period of 8 
hours. The volume supplemented was calculated based the following 
calculation-50 ml/kg for mild dehydration, 20 ml/kg for phototherapy 
allowance and half of the eight hours daily maintenance fluid which totaled 
to approximately 80ml/kg of fluid supplementation over 8 hours. In 
addition, the infant continued to receive feeds as were given before entry 
into the study. In the study group at the end of the 8-hour period, hydration 
status was once again reassessed and the IV fluids were discontinued. 
Thereafter the baby continued to receive breast or formula feeds as before 
and in addition was given 30 mL/kg/day of extra oral feeds (expressed 
breast milk or formula milk) until the time phototherapy was discontinued. 
The control group was continued on breast or formula feeds ad libitum as 
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was given prior to the randomization procedure. They showed a significant 
reduction in the need for blood exchange transfusion and the duration of 
phototherapy in the study group. This was particularly true when the serum 
osmolality was >290 mOsm/kg, which occurs with subclinical 
dehydration. However they reported higher incidence of hyponatremia 
with the use of 0.2% saline in 5% dextrose as fluid for supplementation as 
it is hypotonic. Hence in our study we chose N/3 saline in 5% dextrose 
based on the suggestion of subsequent studies, for fluid supplementation in 
the extra fluid group. The quantity of the fluid was the same as in this 
study. The results were similar to this study. At the same time the risk of 
hypo/hypernatremia was avoided by the use of N/3 (0.3%) saline in 5% 
dextrose. 
In the study done by Saeidi et al (33), wherein term neonates with severe 
hyperbilirubinemia in the study group were given IV fluid supplementation 
of atleast 80ml/kg over 24 hours, significant reduction in serum bilirubin 
levels in the first 24 hours was demonstrated though there was no change 
in the need for blood exchange transfusion. In our study we were able to 
show a significant reduction in the need for blood exchange transfusion as 
well, in addition to significant reduction in serum bilirubin and duration of 
phototherapy. This is perhaps because though the amount of fluid was 
almost similar to this study, it was given over a shorter time period of 8 
hours in our study. 
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Saini et al (34) did a sub study based on two earlier studies of IV fluid 
supplementation in newborns with severe hyperbilirubinemia, one 
published and one unpublished. They analysed the causes for the failure of 
IV fluid supplementation. By multiple logistic regression model they 
concluded that Fluid supplementation for severe non-hemolytic 
hyperbilirubinemia is less likely to be successful in preventing BET in full-
term neonates born by cesarean or instrumental delivery as compared to 
babies born by normal vaginal delivery. In our study the normal vaginal, 
instrumental and cesarean deliveries were evenly distributed between the 
extra fluid group and the control group, thus eliminating the bias due to 
mode of delivery. 
Demirsoy et al (35) carried out a randomized controlled study on effect of 
IV fluid supplementation during phototherapy on breast fed term neonates 
with severe hyperbilirubinemia. They did not find a significant reduction in 
fluid supplementation group and the control group in the rate of exchange 
transfusion and duration of phototherapy, irrespective of the serum 
osmolality (>or<290 mOsm/kg). The quality and the amount of fluid given 
was the same as employed in the study by Mehta et al. This difference 
could be due to lower mean of serum osmolality levels in both study and 
control groups and higher exchange cut off  of >25mg/dL used in this 
study. In our study though we did not measure the serum osmolality and 
we used almost the same criteria for exchange as was used by Mehta et al. 
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We found the results to be almost the same in our study with significant 
reduction in the rates of blood exchange transfusion and the duration of 
phototherapy in the fluid supplementation group compared to the control 
group.  
Al-Masri (36) conducted a study to find out if it was necessary to 
supplement healthy term infants with fluid during phototherapy? They 
concluded that there was no need to add extra fluid during phototherapy, as 
they did not find statistically significant decline in serum bilirubin at 
identical time points among supplemented and the non-supplemented 
groups. Though the fluid used was the same as in earlier studies, the 
amount of extra fluid given to the supplemented group was only 20% of 
the maintenance. Again this was almost similar to the amount of fluid used 
by Iranpour et al and the results were identical in these two studies. Had 
higher amount of fluid been used in accordance with mild dehydration 
principle, the results could have been the same as observed in the study by 
Mehta et al and also in our study. 
Balasubramanian et al (37) carried out the study with two different types 
of fluid for fluid supplementation in the two groups as 0.2% saline in 5% 
dextrose in one group (hypotonic fluid group) and 0.9% saline in 5% 
dextrose in the other group (isotonic fluid group) of term babies with 
severe hyperbilirubinemia. The fluid supplementation was carried out for 8 
hours with the same amount as was used by Mehta et al in their study. 
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They found that the rate of blood exchange transfusion and the duration of 
phototherapy was the same in both the groups which was also similar to 
the study by Mehta et al. however they observed that Proportion of 
neonates developing hyponatremia after 8 hours of IV fluid 
supplementation was significantly higher in hypotonic fluid group as 
compared to isotonic fluid group (48.8% vs. 10.5%) and proportion 
developing hypernatremia in isotonic fluid group was also significantly 
higher (39.5% vs. 12.2%). Hence their inference was an ideal fluid would 
be of a strength which was between normal saline and 0.2% saline. Based 
on the study by Aperia et al. (40), a term healthy neonate of 3 kg could 
excrete a maximum of 12 mEq of sodium over 8 hours in urine. An ideal 
fluid for supplementation in such neonates could be N/3 (0.3%) saline in 
5% dextrose, which would then give a sodium load of 4 mEq/kg over 8 
hours (12.2 mEq for a 3 kg neonate). Based on this post hoc analysis, they 
suggested that N/3 (0.3%) saline in 5% dextrose might carry the least risk 
of hyponatremia as well as hypernatremia and hence could be the fluid of 
choice for fluid supplementation.   
This formed the basis of our research. We were able to prove in a 
randomized controlled trial that IV fluid supplementation in neonates with 
severe non-hemolytic hyperbilirubinemia with 0.3% saline in 5% dextrose 
significantly reduced the risk of blood exchange transfusion and duration 
of phototherapy without causing disturbances in sodium homeostasis. 
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Though no IV site complications were observed in our study, it is a known 
source of nosocomial sepsis. Hence strict adherence to asepsis practices 
and vigilant monitoring is a must to carry out this adjunctive method of 
management of severe hyperbilirubinemia in newborn babies. 
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LIMITATIONS OF THE STUDY 
1. The study was conducted with a power of 80%. A larger sample 
size with 90% power would add more meaningful strength to the 
observations in this study. 
2. The oral intake could not be strictly monitored as all babies were 
breastfed at libitum and no extra EBM or formula feeds were used 
as per the baby friendly hospital initiative. 
3. The serum osmolality which generally tends to become >290 
mOsm/kg with subclinical dehydration, could not be measured in 
our study. Hence we could not do a subset analysis of whether fluid 
supplementation was more useful in this group of babies. 
4.  We did not have oral fluid supplementation limb in our study. As 
suggested by some studies, the possibility of supplementation of 
extra fluids in the form of EBM or accepted equivalent by oral route 
alone in babies with severe hyperbilirubinemia needs to be further 
explored. 
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CONCLUSIONS 
 
1. The IV fluid supplementation with 0.3% saline in 5% dextrose in 
newborns with severe non-hemolytic hyperbilirubinemia was useful 
in significantly reducing the need for blood exchange transfusion.  
(p = 0.001) 
2. In addition the total duration of phototherapy reduced significantly 
in the fluid supplementation group (p = 0.013) 
3. More percentage drop in serum bilirubin was observed in the fluid 
supplementation group at 4, 8 and 24 hrs of study (p = 0.001, 0.001 
and 0.049). 
4. Moreover the use of 0.3% saline in 5% dextrose as fluid for 
supplementation did not lead to any significant disturbances in 
sodium homeostasis in the form of hyponatremia or hypernatremia 
at 8 and 24 hours of study, which could be detrimental to the 
neonates. (p = 0.767 and 0.419). N/3 (0.3%) saline in 5% dextrose 
appears to be the ideal fluid of choice for fluid supplementation in 
term neonates with non-hemolytic severe hyperbilirubinemia. 
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To conclude, this study reinforces the effectiveness of IV fluid 
supplementation in full term neonates with severe non-hemolytic 
hyperbilirubinemia in reducing the rate of blood exchange transfusion and 
the duration of phototherapy and further adds a new dimension regarding 
the usefulness of 0.3% saline in 5% dextrose as supplementary fluid of 
choice in maintaining the sodium homeostasis. 
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PROFORMA 
Patient n. _______                                  Hospital                                  ICH        
Date____________                                                                                  IOG       
 
Group of Randomization:      Supplemental Fluid therapy Group  
                                                                               Control Group       
Name  ______________________________Date of birth __________________ 
Gender:_____________________________Time of birth __________________ 
 
Obstetric history: 
Maternal age___G_P_L_A_Previous pregnancies, n. __Previous deliveries, n. __ 
 
Antenatal history: 
Maternal hypertension/Preeclampsia, (yes/no) _____ Diabetes, (yes/no) ______ 
Placenta abruptio, (yes/no) __ Maternal anemia, (yes/no)____Other, (specify)__  
 
Amniotic fluid: Clear     Meconium stained    Other, (specify)________   
 
Mode of delivery: Vaginal  ________Caesarean section  (reason): _________ 
 
Gestational age (wks)______Birth weight (g) ________Present weight(g)______ 
 
Breastfeeding: Yes  (full __/ partial ___) No  
 
TSB: 
At Enrolment____________Time_____________DOL/HOL_________________ 
After 4 hours____________ 
After 8 hours____________ 
After 12 hours___________ 
After 24 hours___________ 
After 36 hours___________ 
After 48 hours___________ 
After 60 hours___________ 
After 72 hours___________ 
After 84 hours___________ 
At discontinuing PT_______ 
 
Blood Grouping and Typing: Baby______________Mother_________________  
DCT________________________ 
CBC WITH PS______________________________________ 
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Serum Sodium, At Enrolment_____________ 
                          After 8 hours_____________ 
                          After 24 hours____________ 
Blood Exchange Transfusion      Required              
                                                     Not Required       
 
Diagnosis at discharge: _____________________________________  
 
Date _____________ 
 
 
Complications: No   Yes   
 
Nature of Complications:_____________________________________________ 
 
Comments: 
________________________________________________________________ 
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ABBREVIATIONS: 
 
RCT = Randomized Controlled Trial 
 
AGA = Appropriate for Gestational Age 
 
TSB = Total Serum Bilirubin  
 
BET= Blood Exchange Transfusion  
 
DVET = Double Volume Exchange Transfusion 
 
PT = Phototherapy 
 
RBC = Red Blood Cell 
 
UDPGT = Uridine Diphosphoglucuronosyl Transferase 
 
ABE = Acute Bilirubin Encephalopathy 
 
BIND = Bilirubin Induced Neurological Dysfunction 
 
AAP = American Academy of Pediatrics 
 
IVIG = Intravenous Immunoglobulin  
 
IV = intravenous 
 
EBM = Expressed Breast Milk 
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PATIENT INFORMATION SHEET 
Title: 
A Randomized Controlled Trial of Fluid Supplementation in Term Neonates with Severe 
Hyperbilirubinemia with N/3 (0.3%) saline in 5%Dextrose 
    Jaundice is a common problem in newborns. High levels of jaundice in babies can cause 
damage to the infant’s brain. To prevent this phototherapy is the standard mode of treatment 
for jaundiced babies. In spite of phototherapy sometimes, jaundice does not come down and 
the baby requires an invasive procedure called blood exchange transfusion, which has its own 
inherent complications. There is a suggestion that breast fed babies given IV supplemental 
fluids and phototherapy can quickly cause decline in bilirubin and prevent blood exchange 
transfusion and hence its related complications. This study is to compare the efficacy of IV 
supplemental fluids and phototherapy when compared to phototherapy alone in preventing 
blood exchange transfusion.     
   Term neonates with high levels of non hemolytic jaundice with no signs of clinical dehydration 
after randomization shall be either given supplemental fluid therapy along with breast feeds at 
libitum while under standard phototherapy (interventional group) or only breast feeds at 
libitum  while under standard phototherapy (control group). The primary and secondary 
outcomes will be studied in both the groups. 
   We would be happy if could make your baby a part of this study. We assure you that we 
would take utmost care to see that your baby is not harmed in any way throughout the study. A 
little amount of blood (around 2 ml) will be needed from your baby for biochemical 
investigations required to be done in the study. No harm will be rendered to your baby due to 
this.                       
     There is no compulsion. You can withdraw from the trial at anytime during the study. Your 
baby will continue to receive routine care given to a jaundiced baby as per the hospital 
protocol. During the study, during the analysis of the results and during the publication of the 
study your identity will not be revealed. 
    The outcome of the study will be revealed to you after the completion of the study if 
requested for. 
 
Signature of the Investigator                                                             Signature of Parent 
Contact Address: 
Dr. Mohamed Sajjid 
D.M. Neonatology post graduate 
I.C.H.&H.C, Egmore, Chennai- 8. 
Mobile No.:9841318084. 
 
Date : 
 
Place : Chennai -8. 
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CONSENT FORM 
Title: 
 
A Randomized Controlled Trial of Fluid Supplementation in Term Neonates with Severe 
Hyperbilirubinemia with N/3 (0.3%) saline in 5%Dextrose 
 
I Ms/Mr.__________________________ M/O/F/O, B/O ____________________________ 
Sex___________Hosp. No.________________ admitted in ICH, Egmore on ____________ 
was explained to by the doctor that my baby is being enrolled in fluid supplementation 
study for jaundice. 
I have received the Patient Information Sheet from the doctor regarding the study 
“I am willing for my child to be enrolled in fluid supplementation study for jaundice. The 
doctors have explained to me the nature and the purpose of the trial. 
I have given my consent only after completely understanding the details that were 
explained to me.  
I am willing for my baby to be enrolled in this study without any ones compulsion.  
I am fully aware that I can withdraw from the trial at any time during the study and 
routine care will be continued. 
I have given consent for usage of fluid supplementation for jaundice as per the study 
protocol.  
I have also given my consent for drawing blood sample for biochemical analysis during the 
study if needed. 
The rare complications which can arise was explained to me. 
I have given this consent to be enrolled in this study with my full consciousness.  
 
 
Signature of the Investigator                                                          Signature of Parent 
Date : 
Place: Chennai -8. 
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Muha;r;rp jfty; jhs; 
 
 gr;rpsk; FHe;ijfs; bghJthf k";rs; fhkhiy ghjpg;g[f;F MshFk;. 
jPtpu k";rs; fhkhiy FHe;ijapd; \isia ghjpf;ff; ToaJ. bghJthf 
k";rs; fhkhiyia Fiwg;gjw;fhf nghl;nlh bjugp (xspf; fjph;) vDk; 
rpfpr;ir nkw;bfhs;sg;gLk;. Muha;r;rpahsh;fs; euk;g[ tHpahf FSf;nfh!; 
brYj;jp k";rs; fhkhiyia Fiwf;f Koa[kh vd Kad;W tUfpd;wdh;. 
,jd; bjhlh;r;rpahf gr;rpsk; FHe;ijfSf;F k";rs; fhkhiy gw;wp xU 
Muha;r;rp FHe;ijfs; ey kUj;jtkidapy; eilbgw ,Uf;fpwJ. ,e;j 
Muha;r;rpapy; gr;rpsk; FHe;ijfs; ,U FGf;fshf gphpf;fg;gl;L rpfpr;iff;F 
cs;shthh;fs;. xU gphptpdUf;F euk;g[ tHpahf FSf;nfh!; kw;Wk; 
nghl;nlh bjugp (xspf;fjph;) bfhLj;Jk;/ kw;Wk; xU gphptpdUf;F nghl;nlh 
bjugp (xspf;fjph;) kl;Lnk bfhLf;fg;gLk;. ,U gphptpdUf;Fk; jha;g;ghy; 
bfhLf;fg;gLk;. Fwpg;gpyhf;fk; Kiwapy; njh;t[ bra;ag;gl;L c';fs; 
FHe;ijf;F VnjDk; xU gphptpy; cs;s rpfpr;ir jug;gLk;. FHe;ijf;F 
k";rs; fhkhiy Fiwa[k; tiu rpfpr;irj; jug;gLk;. nkYk; FSf;nfh!; 
Vw;Wk; gphptpy; gf;ftpist[fs; tUkh vd;gjid Muha;r;rp \yk; 
fz;lwpag;gLfpwJ.  
 c';fs; FHe;ija[k; ,e;j Muha;r;rpapy; g';nfw;f eh';fs; 
tpUk;g[fpnwhk;. ,e;j Muha;r;rpapd; \yk; c';fs; FHe;ijapd; nehapd; 
Ma;twpf;ifnah my;yJ rpfpr;irnah ghjpg;gpw;F Vw;glhJ vd;gija[k; 
bjhptpj;Jf; bfhs;fpnwhk;. 
 Kot[fis my;yJ fUj;Jf;fis btspapLk; nghnjh my;yJ 
Muha;r;rpapd; nghnjh j';fspd; FHe;ijapd; milahs';fisnah my;yJ 
j';fsJ kidtpapd; bgaiunah (FHe;ijapd; bgaiu) btspapl 
khl;nlhk; vd;gija[k; bjhptpj;Jf; bfhs;fpnwhk;. 
 ,e;j Muha;r;rpapy; g';nfw;gJ j';fSila tpUg;gj;jpd; nghpy; jhd; 
,Uf;fpwJ. nkYk; eP';fs; ve;neuKk; ,e;j Muha;r;rpapypUe;J gpd; 
th';fyhk; vd;gija[k; bjhptpj;Jf; bfhs;fpnwhk;. 
 ,e;j Muha;r;rpapd; Kot[fis Muha;r;rpapd; nghJ my;yJ 
Muha;r;rpapd; Kotpd; nghJ j';fSf;F mwptpg;nghk; vd;gija[k; 
bjhptpj;Jf; bfhs;fpnwhk;.  
 
 
 Muha;r;rpahsh; g';nfw;ghsh; ifbahg;gk; 
 kU. KfkJ rh$pj; 
 gr;rpsk; FHe;ijfs; gphpt[  
 FHe;ijfs; ey kUj;Jtkid 
 vGk;g{h;/ brd;id – 8. 
 bry; - 9841318084. 
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Muha;r;rp xg;g[jy; fojk; 
 
Muha;r;rp jiyg;g[ :  jPtpu k";rs; fhkhiyahy; ghjpf;fg;gl;l epiw 
khjk; Md FHe;ijfSf;F euk;g[ thapyhf FSf;nfh!; brYj;Jjy; 
kw;Wk; nghl;nlh bjugp (xspf;fjph;) my;yJ nghl;nlh bjugp (xspf;fjph;) 
kl;Lk; jug;gLk; rpfpr;ir bjhlh;ghd Muha;r;rp. 
 
bgah; : njjp : 
taJ : cs;nehahsp vz;. : 
ghy; :  Muha;r;rp nrh;f;if vz;. : 
  
     ,e;j Muha;r;rpapd; tptu';fSk; mjd; nehf;f';fSk; KGikah 
vdf;F bjspthf tpsf;fgl;lJ. ,jpy; ,U FGf;fshf gr;rpsk; 
FHe;ijfs; gphpf;fg;gLthh;fs; vd;gij mwpe;njd;. ,jpy; VnjDk; xU 
FGtpy; Fwpg;gpyhf;fk; Kiwapy; vdJ FHe;ij g';F bfhs;tjpy; ehd; 
rk;kjk; bjhptpf;fpnwd;. vdf;F tpsf;fg;gl;l tp#a';fis ehd; g[hpe;J 
bfhz;L ehd; vdJ rk;kjj;ij bjhptpf;fpnwd;. 
  
 ,e;j Muha;r;rp gpwhpd; eph;ge;jkpd;wp vd; brhe;j tpUg;gj;jpd; 
nghpy; jhd; g';F bgWfpnwd; kw;Wk; ehd; ,e;j Muha;r;rpapy; ,Ue;J 
ve;neuKk; gpd;th';fyhk; vd;gija[k; mjdhy; ve;j ghjpg;g[k; Vw;glhJ 
vd;gija[k; ehd; g[hpe;J bfhz;nld;. 
 ehd; gr;rps'; FHe;ijapd; k";rs; fhkhiy Fwpj;j ,e;j 
Muha;r;rpapd; tptu';fis bfhz;l jfty; jhis bgw;Wf; bfhz;nld;. 
 ehd; vd;Dila Raepidt[ld; kw;Wk; KG Rje;jpuj;Jld; ,e;j 
kUj;Jt Muha;r;rpapy; vd; FHe;ijia nrh;j;Jf; bfhs;s 
rk;kjpf;fpnwd;. 
 ,e;j Muha;r;rpapy; vdJ FHe;ijf;F ,uj;jk; vLg;gjw;F KG 
rk;kjj;ij bjhptpj;J bfhs;fpnwd;. vdJ FHe;ijf;F Muha;r;rpapd; 
\yk; VnjDk; gpd; tpist[fs; Vw;glyhk; vd kUj;jth; \yk; 
bjhpe;J bfhz;nld;. 
 
 
 
njjp ifbahg;gk;  
 
S NO. NAME GENDER HOSPITAL IM/EM GROUP  MATERNAL  AGE GRAVIDA PARA LIVEBIRTHS MATERNAL HTN MATERNAL DM MATERNAT APH MATERNAL ANEMIA AMNIOTIC FLUID MODE OF DELV
1 B/O PADMAVATHY 2 1 1 2 25 2 2 2 2 2 2 2 1 VACUUM
2 B/O JEEVITHA 1 1 1 1 26 PRIMI 1 1 2 2 2 2 1 VAGINAL
3 B/O GOMATHI 2 1 1 1 20 2 2 2 2 2 2 2 1 VAGINAL
4 B/O SARITHA 1 1 1 2 25 2 2 2 2 2 2 2 1 ELECTIVE LSCS
5 B/O MONIKA 2 1 1 1 20 PRIMI 1 1 2 2 2 2 1 VAGINAL
6 BABY MITHUN 1 1 1 2 27 PRIMI 1 1 2 2 2 2 1 VAGINAL
7 BABY DEVIKA 2 1 1 2 20 PRIMI 1 1 2 2 2 2 1 VAGINAL
8 B/O YASERA BEGUM 1 1 1 1 27 2 2 2 2 2 2 2 1 VAGINAL
9 B/O HEMALATHA 2 1 1 2 19 PRIMI 1 1 2 2 2 2 1 ELECTIVE LSCS
10 B/O KUMARI TWIN 1 2 1 1 1 27 PRIMI 1 1 2 2 2 2 1 ELECTIVE LSCS
11 B/O THENMOZHI 1 1 1 1 19 PRIMI 1 1 2 2 2 2 1 VAGINAL
12 B/O BANUMATHI 2 1 1 2 26 PRIMI 1 1 2 2 2 2 1 VAGINAL
13 B/O REJI 1 1 1 2 24 2 2 2 2 2 2 2 1 ELECTIVE LSCS
14 B/O PANCHAVARNAM 2 1 1 2 26 2 1 1 2 2 2 2 1 ELECTIVE LSCS
15 B/O THILAGAM 1 1 1 2 27 PRIMI 1 1 2 2 2 2 1 VAGINAL
16 B/O SATHYA 1 1 1 1 21 2 2 2 2 2 2 2 1 VAGINAL
17 B/O PAPAATHI 1 1 1 1 27 PRIMI 1 1 2 2 2 2 1 ELECTIVE LSCS
18 B/O KAVITHA 2 1 1 2 24 PRIMI 1 1 2 2 2 2 1 VAGINAL
19 B/O SARANYA 2 1 1 1 20 PRIMI 1 1 2 2 2 2 1 VAGINAL
20 B/O LAKSHMI 2 1 1 2 26 3 3 3 2 2 2 2 1 VAGINAL
21 B/O BENAZEER 1 1 1 1 20 PRIMI 1 1 2 2 2 2 1 VAGINAL
22 B/O GUNAVATHY 1 2 2 1 32 PRIMI 1 1 2 2 2 2 1 VAGINAL
23 B/O KARPAGAM 1 1 1 2 23 2 2 2 2 2 2 2 1 ELECTIVE LSCS
24 B/O RAJESHWARI TWIN 2 2 1 1 1 25 PRIMI 1 1 2 2 2 2 1 ELECTIVE LSCS
25 B/O NAGAMMA 2 1 1 1 25 PRIMI 1 1 2 2 2 2 1 VAGINAL
26 B/O MYTHILI 2 2 2 2 24 2 2 2 2 2 2 2 1 ELECTIVE LSCS
27 B/O GEETHA 2 2 2 2 24 2 2 2 2 2 2 2 1 ELECTIVE LSCS
28 B/O BHAVANI 1 1 1 1 26 PRIMI 1 1 2 2 2 2 1 VAGINAL
29 B/O VAGITHA 2 1 1 2 26 2 2 2 2 2 2 2 1 VAGINAL
30 B/O NAGARANI 1 2 2 2 25 2 1 1 2 2 2 2 1 ELECTIVE LSCS
31 B/O RADHIKA 1 2 2 1 26 PRIMI 1 1 2 2 2 2 1 ELECTIVE LSCS
32 B/O SUGANYA 1 2 2 1 29 PRIMI 1 1 2 2 2 2 1 VAGINAL
33 B/O THENMOZHI 2 2 2 1 27 PRIMI 1 1 2 2 2 2 1 EMERGENCY LSCS
34 B/O BAKKIYALAXMI 2 1 1 2 21 PRIMI 1 1 2 2 2 2 1 VAGINAL
35 B/O KOMALAVATHY 1 1 1 2 27 PRIMI 1 1 2 2 2 2 1 EMERGENCY LSCS
36 B/O SUMITHRA 2 1 1 1 23 PRIMI 1 1 2 2 2 2 1 VAGINAL
37 B/O VASANTHI 1 1 1 1 19 PRIMI 1 1 2 2 2 2 1 VAGINAL
38 B/O GAYATHRI 2 2 2 2 26 2 2 2 2 2 2 2 1 ELECTIVE LSCS
39 B/O TAMILSELVI 2 2 2 1 25 2 2 2 2 2 2 2 1 ELECTIVE LSCS
40 B/O DHANALAKSHMI 2 2 2 1 24 3 2 2 2 2 2 2 1 VAGINAL
41 B/O SANGEETHA 1 2 2 2 25 PRIMI 1 1 2 2 2 2 1 VACUUM
42 B/O SHANTIPRIYA 2 2 2 2 20 PRIMI 1 1 2 2 2 2 1 OUTLET FORCEPS
43 B/O VASANTHI 2 2 2 2 25 PRIMI 1 1 2 2 2 2 1 ELECTIVE LSCS
44 B/O JUBETHA 2 1 1 1 23 2 2 2 2 2 2 2 1 VAGINAL
45 B/O GOWRI 2 2 2 2 24 PRIMI 1 1 2 2 2 2 1 EMERGENCY LSCS
46 B/O RADHIKA 2 2 2 1 20 PRIMI 1 1 2 2 2 2 1 VAGINAL
47 B/O SUGANYA 2 1 1 1 19 PRIMI 1 1 2 2 2 2 1 VAGINAL
48 B/O NASEEMA 1 2 2 1 22 PRIMI 1 1 1 2 2 2 1 VACUUM
49 B/O KANAGAVALLI 1 2 2 2 25 2 2 2 2 2 2 2 1 ELECTIVE LSCS
50 B/O BHUVANESWARI 1 2 2 1 23 PRIMI 1 1 2 2 2 2 1 EMERGENCY LSCS
S NO. NAME GENDER HOSPITAL IM/EM GROUP  MATERNAL  AGE GRAVIDA PARA LIVEBIRTHS MATERNAL HTN MATERNAL DM MATERNAT APH MATERNAL ANEMIA AMNIOTIC FLUID MODE OF DELV
51 B/O SIVAMALA 1 2 2 2 30 3 2 2 2 2 2 2 1 ELECTIVE LSCS
52 B/O EZIHILARASI 2 2 2 1 25 PRIMI 1 1 2 2 2 2 1 VAGINAL
53 B/O SHYAMALA 1 2 2 1 25 2 2 2 2 2 2 2 1 ELECTIVE LSCS
54 B/O AISHWARYA 2 1 1 2 22 PRIMI 1 1 2 2 2 2 1 ELECTIVE LSCS
55 B/O KALAIARASI 1 2 2 2 22 PRIMI 1 1 2 2 2 2 1 VAGINAL
56 B/O USHA 1 2 2 2 25 PRIMI 1 1 2 2 2 2 1 OUTLET FORCEPS
57 B/O PARVATHY 2 2 2 1 23 PRIMI 1 1 2 2 2 2 1 OUTLET FORCEPS
58 B/O ARCHANA 1 2 2 1 20 PRIMI 1 1 2 2 2 2 1 VAGINAL
59 B/O DEEPIKA 1 2 2 1 21 PRIMI 1 1 1 2 2 2 1 EMERGENCY LSCS
60 B/O JESSY 2 2 2 2 23 3 2 2 2 2 2 2 1 EMERGENCY LSCS
61 B/O RAJESWARI 1 2 2 2 26 PRIMI 1 1 1 2 2 2 1 EMERGENCY LSCS
62 B/O MUTHULAKSHMI 2 1 1 2 29 PRIMI 1 1 2 2 2 2 1 EMERGENCY LSCS
63 B/O RAJESHWARI 1 2 2 1 26 PRIMI 1 1 2 2 2 2 1 LMC FORCEPS
64 B/O RAJALAXMI 2 1 1 1 24 2 2 2 2 2 2 2 1 VAGINAL
65 B/O AMUDHA PAULIN 1 1 1 2 23 PRIMI 1 1 2 2 2 2 1 ELECTIVE LSCS
66 B/O SANDHIYA 1 1 1 2 25 3 3 3 2 2 2 2 1 VAGINAL
67 B/O PRIYA 2 2 2 1 23 PRIMI 1 1 2 1 2 2 1 VAGINAL
68 B/O CHANDRA 2 2 2 2 25 PRIMI 1 1 2 2 2 2 1 VAGINAL
69 B/O AMEENA BEE 1 2 2 2 27 PRIMI 1 1 1 2 2 2 1 VAGINAL
70 B/O YAMUNA 2 2 2 1 22 3 3 2 2 2 2 2 1 VAGINAL
71 B/O ELLAMMAL 1 2 2 2 26 PRIMI 1 1 2 2 2 2 1 VAGINAL
72 B/O GOVINDAMMAL 1 2 2 1 24 2 1 1 2 2 2 2 1 VACUUM
73 B/O VINNARASI 1 2 2 1 19 PRIMI 1 1 2 2 2 2 1 VAGINAL
74 B/O KAVITHA 1 1 1 2 24 PRIMI 1 1 2 2 2 2 1 VAGINAL
75 B/O KARPAGAVALLI 2 1 1 1 23 2 2 2 2 2 2 2 1 ELECTIVE LSCS
76 B/O POORNIMA 1 1 1 1 26 2 2 2 2 2 2 2 1 VAGINAL
77 B/O DEVI 2 1 1 2 22 3 3 3 2 2 2 2 1 VAGINAL
78 B/O REVATHY 1 1 1 2 27 PRIMI 1 1 2 2 2 2 1 VAGINAL
79 B/O NITHYA 1 1 1 2 22 2 2 2 2 2 2 2 1 VAGINAL
80 B/O CHITRA 2 1 1 1 26 3 3 3 2 2 2 2 1 VAGINAL
81 B/O LATHIKA 2 1 1 1 22 PRIMI 1 1 2 2 2 2 1 VAGINAL
82 B/O RAMANI 1 1 1 2 26 PRIMI 1 1 2 2 2 2 1 OUTLET FORCEPS
83 B/O MUNIYENDRA 1 1 1 1 21 PRIMI 1 1 2 2 2 2 1 EMERGENCY LSCS
84 B/O SUMATHI 1 1 1 2 27 PRIMI 1 1 2 2 2 2 1 VAGINAL
 GA BW PW % WT LOSS BF AGE ONSET AGE INCL TSB 0 HRS TSB 4 HRS % FALL 4 HRS TSB 8 HRS % FALL 8 HRS TSB 24 HRS % FALL 24 HRS BET PT DURATION
40.6 2600 2510 3.5 1 3 4.7 22.8 19.8 13 17 25 14.8 35 2 24
38.7 3250 2990 8 1 4 4.7 25 19.5 22 16.5 34 13 48 2 24
38 2700 2500 7.4 1 3 7.5 24.2 18.9 22 18 25 14.1 41 2 24
39.8 3016 3000 0.5 1 4 4.5 25 27 NA NA NA NA NA 1 NA
38.4 2500 2400 4 1 3 3.5 21.6 17.8 17 16.8 22 12.3 43 2 24
38 2600 2500 3.8 1 4 7.5 21.5 23.5 NA NA NA NA NA 1 NA
38 2500 2400 4 1 3 9.5 20.7 16.4 20 16.4 20 16.3 21 2 48
40 2750 2720 1 1 3 3.5 22.2 16.5 25 16.5 25 15.9 28 2 36
39.8 3000 2830 5.7 1 1.5 2 23.3 23 1 23 NA NA NA 1 NA
39 2500 2260 9.6 1 3 3.5 24.8 28 NA NA NA NA NA 1 NA
40 3750 3720 0.8 1 3 3.5 23.4 22.6 3 22 6 14.8 36 2 36
38 3600 3320 7.7 1 3 6.5 23.6 26.4 NA NA NA NA NA 1 NA
38.8 2700 2400 11 1 2 3.3 20.5 19 7 14.6 28 14 31 2 36
40.3 2860 2800 2 1 2 3.5 21 23.8 NA NA NA NA NA 1 NA
38.8 2900 2720 6.2 1 1.5 2.2 20.1 22.1 NA NA NA NA NA 1 NA
38 3250 3200 1 1 3 4.5 23.8 19.2 19 18.1 24 15.8 33 2 36
38 3250 3000 7.7 1 2 3 23.7 21.4 9 18 24 14 41 2 24
39.8 2660 2630 1.1 1 4 5.5 20.2 19 6 18.1 11 15.1 25 2 24
40.4 2500 2300 8 1 3 5.5 20.3 18 11 16.8 17 15 26 2 24
40 3000 2850 5 1 4 5.5 25 27.6 NA NA NA NA NA 1 NA
38 2600 2400 7.7 1 3 5.9 20.8 18.5 11 16.6 20 11.8 43 2 24
38 2900 2700 6.9 1 1.5 2 20.2 18 10 16.8 17 12.3 39 2 24
39.8 2750 2650 3.6 1 2 3 22.5 20.5 8 19.6 9 12.3 45 2 24
38 2500 2250 10 1 4 5 20.1 18.1 10 16.8 16 14.1 30 2 24
39.3 3000 2900 3.3 1 5 6.5 23.9 20.4 14 20.4 14 15.8 34 2 36
39 3250 3060 5.8 1 3 4.5 22.5 21 6 19 15 15 33 2 36
39 3250 2990 8 1 4 5 20.6 19 8 17.8 13 14 32 2 24
38 3250 2990 8 1 2 2.2 20.8 17 18 16.5 20 14.8 29 2 24
40 3100 3030 2.2 1 3 3.5 21.8 20 8 18 17 14 36 2 24
39.4 3500 3245 7.2 1 2 2.9 20.2 22.5 NA NA NA NA NA 1 NA
38 2750 2630 4 1 4 6.5 20.8 19.5 6 18.1 18 14.8 29 2 24
38.7 2800 2700 3 1 3 4.5 22.1 20.1 9 19 14 9.6 56 2 24
38 2700 2485 8 1 1.5 2 20.1 19 5 17.8 11 13.5 33 2 24
39.7 3250 2960 9 1 5 6.5 24.1 23.8 1 24.1 NA NA NA 1 NA
40 2700 2530 5 1 2 2.6 25 24 4 25 NA NA NA 1 NA
38.4 2750 2550 7 1 3 3.5 22.1 18 18 16 28 13.8 37 2 24
38.6 2500 2250 10 1 4 7.5 24.2 19.8 18 16.8 30 12 50 2 24
38 2600 2395 7.9 1 3 4 20.1 19 5 18.5 8 12.5 37 2 36
38 2500 2250 10 1 3 5.5 20.1 18.1 10 16.8 16 13.3 34 2 24
39 3200 3100 3.1 1 1.5 2 23.8 18.1 24 16.1 32 12 49 2 24
38 2700 2650 1.8 1 2 2.8 20.4 19.8 3 18.5 9 15 26 2 36
39.3 3105 2860 7.9 1 3 4 20.1 18.4 8 16.8 16 13 35 2 24
38.4 2700 2450 9.2 1 3 4.5 21.3 20 6 18.8 12 15.8 26 2 36
40 3060 3000 1.9 1 1.5 1.9 20.4 18 12 17 17 13 36 2 24
40 2500 2400 4 1 2 3 20.7 19 8 18.1 12 10 52 2 24
40 3200 3130 2.2 1 4 8.5 22.1 18 18 13.8 37 12 46 2 12
38 2500 2440 2.4 1 4 6.5 24.4 22.2 9 17.8 27 15 38 2 36
38.4 3500 3300 5.7 1 3 4 20.1 18.8 6 18 10 14.1 30 2 24
38.3 2500 2250 10 1 3 4.5 25 23.8 5 26.4 NA NA NA 1 NA
41 3800 3690 2.9 1 3 3.5 21.8 20.1 8 17 22 9 59 2 24
 GA BW PW % WT LOSS BF AGE ONSET AGE INCL TSB 0 HRS TSB 4 HRS % FALL 4 HRS TSB 8 HRS % FALL 8 HRS TSB 24 HRS % FALL 24 HRS BET PT DURATION
38 2700 2480 8.1 1 4 6.5 24.6 23 6 21.8 11 17 31 2 48
38 3690 3375 8.5 1 3 5.5 20.3 18.1 11 16 21 15 26 2 12
38 3300 2995 9.2 1 3 4.5 22 20 9 18 18 14 36 2 24
40 3200 2990 6.6 1 2.5 3.5 25 24 4 26.7 NA NA NA 1 NA
38 2500 2300 8 1 3 4.5 22 20.8 5 19 14 15 32 2 36
38 2500 2400 4 1 3 3.5 20.1 19.9 1 18.1 10 14 30 2 24
40 2500 2300 8 1 2 3.5 24.2 21 13 19.6 19 14 42 2 24
38 2900 2710 6.5 1 3 4 21.2 19.1 10 16.7 21 14.1 33 2 24
39 3100 2980 3.9 1 2 3.5 20.6 18 13 16.8 18 14 32 2 24
39.8 2750 2600 5.4 1 2 3.5 25 23.8 5 21.9 12 17 32 2 48
38.3 2600 2435 6.3 1 2 3.5 20.7 18.7 10 17 18 14 32 2 24
38 2500 2350 6 1 3 4.5 23.4 23 2 23 NA NA NA 1 NA
38 2700 2500 7.4 1 3 4.5 21.3 20 6 18 15 14.2 33 2 24
38 2530 2300 9 1 2 3.5 22.6 20.9 7 18.7 17 17.4 23 2 48
39.3 3480 3400 2.3 1 3 4.7 25 24 4 24 NA NA NA 1 NA
38.3 3500 3200 8.5 1 3 4 23.4 22.4 4 23.4 NA NA NA 1 NA
38 3530 3230 8.5 1 4 5 25 23 8 20 20 15 40 2 36
39 2940 2850 3 1 3.5 4.5 22 21 4 19.8 10 13.4 39 2 36
40.3 3110 2905 6.6 1 2 3 20.3 19 6 18 11 15 26 2 36
39.7 2750 2600 5.4 1 3 5.2 25 23.1 8 20 20 13 48 2 36
40.3 2750 2590 5.8 1 2 2.9 25 24.6 2 28 NA NA NA 1 NA
38 2600 2350 9.6 1 4 5 20.1 18.1 10 16.4 18 12 40 2 24
39 2870 2790 2.8 1 3 4.5 23.2 18.4 21 18.4 21 15.2 34 2 24
38 2750 2500 9 1 3 3.5 20.6 19 8 17.8 13 14 32 2 24
40 2800 2730 2.5 1 2.5 3.2 20.9 18.2 13 16.8 20 14 33 2 24
40 3200 3050 4.7 1 4 5 20.8 18 15 16.8 19 13 37 2 24
40 3400 3100 8.8 1 4 6.5 20.8 18.1 13 16.5 21 14 33 2 24
38 3200 3010 5.9 1 3 4.8 20.5 20 2 22.5 NA NA NA 1 NA
38.3 3000 2830 5.7 1 3 4.5 20.3 20.1 1 18.1 10 12.4 39 2 36
39.6 3050 2920 4.3 1 3 4.5 20.2 18.1 10 17 16 14 31 2 24
39 2750 2600 5.4 1 4 6.5 20.4 18.2 11 16.6 19 14 31 2 24
39 2500 2340 6.4 1 3 4.5 20.2 18.8 7 17 16 11.7 42 2 24
39.1 2500 2440 2.4 1 2.5 3.7 20.7 18.1 12 16.8 19 10.5 49 2 24
38 2500 2360 5.6 1 3 4.5 20.8 18.8 10 16.9 19 13 37 2 24
BABY BG BABY TYPE MOTHER BG MOTHER TYPE DCT HEMATOCRIT % RC SS 0HRS SS 8 HRS SS 24 HRS COMPLICATIONS
2 1 2 1 2 46.1 2 152 153 150 2
2 1 2 1 2 45.7 2 153 152 150 2
2 1 1 1 2 41.1 2 139 140 139 2
1 1 1 1 2 41 2 137 145 140 2
2 1 1 1 2 42 3 145 150 145 2
1 1 1 1 2 50.5 2 141 153 145 2
1 1 3 1 2 49 3 141 148 145 2
2 1 1 1 2 45 2 136 145 142 2
2 1 1 1 2 43.5 5 146 148 148 2
3 1 1 1 2 42 2 144 138 140 2
3 1 1 1 2 44.7 3 145 143 140 2
3 1 2 1 2 48 2 139 140 141 2
1 1 1 1 2 43 5 143 145 144 2
3 1 1 1 2 42.1 1 147 146 140 2
2 1 1 1 2 49.6 1 151 149 145 2
2 1 1 1 2 52 2 147 148 145 2
3 1 3 2 2 53 3 136 135 135 2
1 1 1 1 2 45 4 144 140 139 2
1 1 1 1 2 45 2 141 142 144 2
1 1 1 1 2 45 2 143 145 145 2
3 1 3 1 2 50.5 2 146 148 145 2
1 2 2 1 2 44 2 141 145 144 2
3 1 3 1 2 53 2 142 141 143 2
4 1 4 1 2 49.7 2 144 145 142 2
1 1 1 1 2 51 2 144 142 143 2
1 1 1 1 2 49.7 2 145 144 142 2
3 1 3 1 2 50 3 138 140 141 2
3 1 1 1 2 47 4 144 145 145 2
3 1 4 1 2 42 3 145 144 139 2
1 1 1 1 2 41.9 2 145 144 142 2
2 1 1 2 2 52 2 140 145 143 2
1 1 1 1 2 44 2 140 145 142 2
3 1 1 2 2 42 3 138 144 140 2
1 1 1 2 2 43.9 2 145 139 140 2
3 1 1 1 2 50.5 2 148 145 144 2
1 1 3 1 2 46 2 135 145 140 2
1 1 3 1 2 48 2 144 145 144 2
3 1 3 2 2 45 3 138 140 141 2
1 1 1 1 2 45 3 144 145 144 2
2 1 1 1 2 45 2 140 145 138 2
2 1 2 1 2 47.7 2 140 142 141 2
1 1 1 2 2 50 2 140 141 142 2
2 1 2 1 2 53 1 140 141 142 2
1 1 1 1 2 48 5 141 140 142 2
2 1 1 1 2 42 2 138 140 142 2
3 1 1 1 2 44.9 2 144 145 138 2
1 1 1 1 2 41 2 146 145 145 2
1 1 2 1 2 50.2 1 140 142 140 2
2 1 1 1 2 42.6 3 145 144 143 2
4 1 3 1 2 48 1 140 141 142 2
BABY BG BABY TYPE MOTHER BG MOTHER TYPE DCT HEMATOCRIT % RC SS 0HRS SS 8 HRS SS 24 HRS COMPLICATIONS
4 1 4 1 2 50.4 2 145 144 143 2
3 1 1 1 2 43.3 2 140 144 138 2
1 1 1 1 2 42.1 2 139 144 140 2
3 1 1 1 2 45.8 2 146 144 145 2
4 1 4 1 2 50.8 2 145 144 140 2
1 1 1 1 2 45 2 140 138 143 2
1 1 1 1 2 45 3 138 145 140 2
2 1 2 1 2 45 1 139 144 142 2
1 1 1 1 2 42.1 2 138 139 140 2
2 1 1 1 2 44.6 2 145 142 144 2
2 1 1 1 2 45 2 145 144 140 2
2 1 1 1 2 47 2 145 140 138 2
1 1 1 1 2 50.9 2 140 145 143 2
2 1 1 1 2 48.8 3 142 140 140 2
2 1 1 1 2 47.7 2 139 140 138 2
2 1 1 1 2 43.8 1 140 138 135 2
3 1 3 1 2 45 2 138 140 142 2
3 1 3 1 2 50 1 145 140 141 2
2 1 2 1 2 45 2 138 140 139 2
2 1 3 1 2 46.9 2 138 140 140 2
3 1 1 1 2 50 2 136 138 140 2
1 1 1 1 2 53 1 140 141 139 2
3 1 3 1 2 52 2 138 141 140 2
1 1 1 1 2 53.5 1 145 144 144 2
2 1 1 1 2 45 2 146 150 145 2
3 1 3 1 2 45 3 145 145 140 2
3 1 1 1 2 44 2 150 148 145 2
1 1 1 1 2 41.1 2 152 144 140 2
2 1 1 1 2 47.9 2 149 146 145 2
1 1 1 1 2 45 1 140 145 140 2
1 1 1 1 2 41 2 144 145 142 2
1 1 1 1 2 45 3 160 161 151 2
2 1 1 1 2 50 2 150 148 145 2
1 1 1 1 2 45 2 143 138 140 2
